We intend to move as fast as science will permit to confirm the benefits of SRP9001 and if successful to rapidly advance this therapy to waiting Duchenne patients around the world Second Quarter 2021 and Recent Corporate Developments Sarepta announced that it concluded its endofphase2 meeting with OTAT In July of 2021 Sarepta completed a successful endofphase2 meeting with the United States Food and Drug Administrations Office of Tissues and Advanced Therapies OTAT regarding the Companys proposed pivotal trial Study SRP9001301 EMBARK and the commercially representative material to be used in that trial